ClinicalTrials.gg
WithdrawnNCT05998941Updated Nov 22, 2023

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

A Phase 2 interventional study of TQB2868 injection and Paclitaxel injection in Cervical Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Withdrawn at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Slow progress in development, the sponsor decided to withdraw and no longer proceed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 456 studies in Uterine Cervical Neoplasms with a site in China — 206 open to participants now, 241 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Enrollment
357th of 361
0 · median 90
Started
2023
with 49 others
Phase 2
137 of 456
71 open now
Registered
295th of 456
by date

Among the 456 studies in Uterine Cervical Neoplasms with a site in China, this one is the 357th largest by enrollment of the 361 interventional ones that give a count, is one of 50 that started in 2023, is one of 137 in phase 2, and was the 295th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 680 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

206 of the 456 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

201 more — sign in →

All 206 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study used a single-arm, open phase II multicenter trial design. All eligible subjects received TQB2868 plus platinum-based chemotherapy with or without bevacizumab. A total of 39 subjects will be enrolled.

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed persistent, recurrent or (International Federation of Gynecology and Obstetrics (FIGO) stage IVB) cervical cancer with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma;
  • It is not suitable for radical treatment such as surgery, radiotherapy and concurrent chemoradiotherapy;
  • No previous systemic therapy for persistent, recurrent or metastatic cervical cancer;
  • Provide archived or freshly obtained tumor tissue samples within the past 2 years or provide traceable test reports;
  • 18 years old ≤75 years old (calculated on the date of signing the ); (ECOG) score 0-1; Expected survival ≥3 months;
  • At least one according to ( (RECIST) 1.1 criteria;
  • The main organs function well and meet the following standards:

    1. Blood routine test criteria (in the case of no blood transfusion and no correction by hematopoietic stimulating factor drugs within 14 days before screening) : (ANC) ≥1.5×109 /L; ≥100×109 /L; ≥100 g/L.
    2. Blood biochemical tests should meet the following criteria: total (TBIL) ≤2× (ULN) (≤3×ULN in Gilbert syndrome patients); (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN. If liver metastasis is present, ALT and AST≤5×ULN; Serum creatinine (Cr) ≤1.5×ULN or ≥60 mL/min; Serum albumin (ALB) ≥30g/L.
    3. Urine routine examination criteria: urine routine indicated that urinary protein \<++; If urinary protein ≥++, it should be confirmed that 24-hour urinary protein quantification ≤1.0 g.
    4. Coagulation function test criteria: (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR) ≤1.5×ULN (no anticoagulant therapy).
    5. Thyroid stimulating hormone (TSH) ≤ ULN; If abnormal, T3 and T4 levels should be examined. If T3 and T4 levels are normal, they can be selected.
    6. Echocardiographic assessment: (LVEF) ≥50%.
    7. 12-lead Electrocardiograph () assessment: interval prolongation (QTc)\<470ms (female).
  • Female subjects of childbearing age should agree to use (such as intrauterine device (IUD), birth control pill or condom) during the study period and within 6 months after the study. A negative serum or urine pregnancy test within 7 days prior to study entry and must be non-lactating.
  • Subjects voluntarily participated in this study, signed informed consent, and had good compliance.

Exclusion criteria

Exclusion Criteria:

  • Tumor disease and medical history:

    1. Have developed or are currently suffering from other malignant tumors within 3 years. The following two cases were included: other malignant tumors treated by single surgery, achieving R0 resection and no recurrence or ; Cured non-melanoma skin cancer, nasopharyngeal carcinoma, and superficial bladder tumors
    2. Other pathological types, such as mucinous adenocarcinoma, clear cell adenocarcinoma, neuroendocrine tumor;
    3. tumor infiltration into the bladder or rectum;
    4. Subjects with known central nervous system (CNS) metastases and/or carcinomatous meningitis;
    5. Patients whose imaging showed that the tumor had invaded important blood vessels or the investigators judged that the tumor was highly likely to invade important blood vessels during the follow-up study and cause fatal hemorrhage;
    6. Uncontrollable pleural, pericardial, or peritoneal effusions requiring repeated drainage.
  • Previous anti-tumor therapy:

    1. Received the last concurrent chemoradiotherapy for radical surgery or postoperative therapy within 3 months before the first medication; Received palliative radiotherapy within 2 weeks before the first dose;
    2. Previously received platinum-based dual agents or any other chemotherapy agents in concurrent chemoradiotherapy for radical purposes;
    3. Received Chinese patent medicine with anti-tumor indications specified in the National Medicinal Products Administration (NMPA) approved drug instructions within 2 weeks before the first drug use;
    4. Prior treatment with anti-angiogenic therapy, therapy, or any treatment targeting immune costimulatory factors, which target the immune mechanism of tumor immune action;
    5. Patients who received immunoregulatory drugs within 2 weeks before the first dose;
    6. Non-resolved toxicity of grade 1 or higher than (CTCAE) due to any previous treatment, excluding alopecia, peripheral sensory impairment.
  • Comorbidities and medical history:

    a. Decompensated cirrhosis and active hepatitis; b. Kidney abnormalities: i. Renal failure requiring hemodialysis or peritoneal dialysis; ii. Presence of hydronephrosis that, in the judgment of the investigator, cannot be resolved by nephrostomy or ureteral stent placement.

    c. Cardiovascular and cerebrovascular abnormalities: i. Myocardial ischemia or myocardial infarction occurred within half a year; ≥ class 2 Congestive heart failure of (NYHA); Arterial thrombotic events block ≥ Grade 2; Arrhythmias that cannot be stably controlled with drugs and those that may potentially affect the trial treatment; ii. Arterial thrombotic events / venous thrombotic events, such as cerebrovascular accident, deep vein thrombosis, and pulmonary embolism, occurred within 6 months; iii. Patients with poor blood pressure control after standard treatment; iv. Previous history of myocarditis or cardiomyopathy. d. Gastrointestinal abnormalities: i. Active or documented inflammatory bowel disease, active diverticulitis; ii. Gastrointestinal perforation, fistula, and intra-abdominal abscess occurred within 6 months before the first medication; iii. The presence of clinical manifestations of gastrointestinal obstruction or the need for routine parenteral rehydration, parenteral nutrition, or indwelling gastric tube.

    e. History of immunodeficiency: i. A history of immunodeficiency, including (HIV) positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; ii. Active disease requiring systemic therapy occurred within 2 years before the first dose. Alternative therapies are not considered systemic treatments; iii. is diagnosed with immunodeficiency or is receiving systemic therapy or any other form of therapy (at a dose >10mg/ day of prednisone or other iso-efficacy hormone) and continues to use it within 2 weeks of the first dose.

    f. Risk of bleeding: i. Bleeding, clotting disease, or current use of warfarin, aspirin, or other antiplatelet drugs within 28 days before the first dose; ii. Patients with any history of bleeding or coagulopathy, regardless of severity; iii. Major surgical treatment or significant traumatic injury within 28 days prior to the first dose, or locally invasive procedure within 1 week), or elective major surgical treatment required during the study; iv. Wounds or fractures that have not healed for a long time. g. Poorly controlled diabetes: fasting blood glucose (FBG) > 10mmol/L; h. Severe active or uncontrolled infection (≥CTC AE grade 2 infection); i. People with known active syphilis and active tuberculosis; j. Previous or existing interstitial pneumonia, (non-infectious) pneumonia requiring corticosteroid therapy, or other pneumonia of grade ≥2; k. Severe reaction after the use of monoclonal antibodies; l. Known to have any to cisplatin/carboplatin or paclitaxel or to be allergic to any of their components; m. Those who have a history of psychotropic drug abuse and cannot quit or have mental disorders; n. Those who suffer from epilepsy and need treatment.

  • Those who participated in clinical trials of other anti-tumor drugs within 4 weeks before the first drug use or did not exceed 5 drug half-lives.
  • History of vaccination within 28 days before the first dose or planned live attenuated vaccine vaccination during the study period.
  • According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or there are other reasons that the subjects are not suitable for enrollment.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TQB2868 injection + Paclitaxel injection + Cisplatin/Carboplatin injection ± Bevacizumab injection

    TQB2868 injection + paclitaxel injection + cisplatin/carboplatin injection ± bevacizumab injection, 3 weeks (21 days) as a treatment cycle.

    Drug: TQB2868 injection · Drug: Paclitaxel injection · Drug: Cisplatin injection · Drug: Carboplatin injection · Drug: Bevacizumab injection

Interventions

06

What researchers measure

Primary outcomes

  1. Investigator-assessed objective response rate (ORR)

    The proportion of subjects who achieve a prespecified reduction in tumor volume and maintain the minimum time requirement, including complete response (CR) and partial response (PR).

    Time frame: Baseline to CR or PR ,about 12 months

Secondary outcomes

  1. Progression free survival (PFS)

    The time between the first dose of medication and disease progression (PD) or death before PD; If there was no PD or death before PD, the date of the last imaging assessment was used as the cutoff date.

    Time frame: Baseline up to PD or death, about 24 months

  2. Disease control rate (DCR)

    The proportion of patients whose tumors shrink or remain stable for a certain period of time, including CR, PR, and stable disease (SD) cases.

    Time frame: Baseline up to PD or death, about 24 months

  3. Duration of response (DOR)

    It refers to the time between the first assessment of the tumor as CR or PR to PD or death before PD in subjects with CR or PR; If subjects with CR or PR did not present with PD or die before PD, the date of the last imaging assessment was used as the cutoff date.

    Time frame: Baseline up to PD or death, about 24 months

  4. Overall survival (OS)

    The time from the first treatment to death from any cause.

    Time frame: Baseline up to die, about 36 months

  5. PFS rate (≥6 months)

    The proportion of patients alive and free of disease progression from the beginning of the first treatment to 6 months.

    Time frame: Baseline up to PD or death, about 24 months

  6. Adverse event rate

    Occurrence of all adverse events (AEs), serious adverse events (SAEs), treatment-related adverse events (TEAEs), and immune-related adverse events (IRaes).

    Time frame: Baseline to the end of the study, about 2 years

  7. European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (QLQ -C30)

    For questions 1 to 28, choose a number from 1 to 4, where 1 means no and 4 means very good. For questions 29 and 30, choose a number from 1 to 7, where 1 means very poor and 7 means very good.

    Time frame: Baseline to the end of the study, about 2 years

  8. European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ -CX24)

    EORTC QLQ-CX24 is a questionnaire for measuring the quality of life of patients with cervical cancer. It has 24 items, including 3 multi-dimensional dimensions of symptoms, body image and sexual/vaginal function, and 6 single-dimensional dimensions of sexual activity, sexual enjoyment, sexual anxiety, lymphedema, menopausal symptoms and peripheral neuropathy. "None" to "very" were scored from 1 to 4, and the score was inversely proportional to the quality of life.

    Time frame: Baseline to the end of the study, about 2 years

  9. EuroQol 5 Dimensions (EQ-5D) Health questionnaire

    EQ-5D is a simple health measure developed by the European Society for Quality of Life. The EQ-5D mainly consists of two parts: the EQ-5D description system and the EQ-5D Visual Analogue Scale (EQ-VAS). The EQ-5D description system describes the health status in five dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. The EQ-VAS is to record the self-rated health status of the respondents. The scale is 0-100, with 0 being "worst imagined health" and 100 being "best imagined health."

    Time frame: Baseline to the end of the study, about 2 years

  10. PD-L1 and TGF-β expression

    PD-1/TGF-β double antibody can increase Leukocyte differentiation antigen 8 (CD8+) T cells in the tumor, reduce immunosuppressive myeloid cells, and inhibit PD-1/PD-L1 pathway on the basis of targeting and neutralizing TGF-β in the tumor microenvironment, which can restore the activity of T cells, enhance the immune response, and more effectively improve the inhibition of tumor.

    Time frame: At baseline

  11. Human papillomavirus (HPV) expression

    The relationship between human papillomavirus and cervical cancer is very close. Persistent infection of high-risk human papillomavirus is one of the high risk factors for cervical cancer.

    Time frame: At baseline

07

Study locations

2 sites
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing 400000, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2023; primary completion for Feb 2025, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2023
First posted
Aug 21, 2023
StartEst.
Aug 2023
Primary completionEst.
Feb 2025
CompletionEst.
Jun 2025
Last update
Nov 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05998941
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Aug 2023 (estimated)
Primary completion
Feb 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Nov 22, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868

Start the discussion